Natural fulvic acids inhibit non-small-cell lung cancer through the COX-2/PGE2/EP4 axis: In silico and in vivo assessments

被引:2
作者
Xin, Pengfei [1 ,2 ]
Wang, Shirui [3 ]
Xu, Xin [3 ]
Liu, Qingmei [1 ,2 ]
Zhang, Caifeng [4 ]
机构
[1] Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Hosp 3, Taiyuan 030032, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China
[3] Shanxi Med Univ, Sch & Hosp Stomatol, Taiyuan 030001, Peoples R China
[4] Taiyuan Normal Univ, Hum Acid Engn & Technol Res Ctr Shanxi Prov, Dept Chem, Jinzhong 030619, Peoples R China
关键词
Fulvic acids; Humic acids; Non -small -cell lung cancer; Molecular docking; EP4; HUMIC SUBSTANCES; EXPRESSION; REVEALS; GROWTH;
D O I
10.1016/j.heliyon.2023.e17080
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: Non-small-cell lung cancer (NSCLC) is a major public health concern with a high inci-dence worldwide. Coal-derived fulvic acids (FAs) contain functional groups in their chemical structures. Overexpression of cyclooxygenases-2 (COX-2), prostaglandin E2 (PGE2), and the PGE2 receptor EP4 subtype (EP4) can have a potential link with the increased tumor incidence and promoted tumor growth and metastasis in NSCLC. This study aimed to assess the biological roles of coal-derived FAs in the growth and development of NSCLC and to elucidate the underlying molecular mechanisms.Methods: A web-based tool for predicting small-molecule pharmacokinetics (pkCSM) was used to analyze the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of FAs. Molecular docking and dynamic simulations were performed to analyze the binding affinities of COX-2 and EP4 to FA. An acute toxicity test and an antitumor study were used to analyze the toxicity and anti-NSCLC effects of FAs. Thirty NSCLC-bearing nude mice were randomly divided into five groups (six mice per group): vehicle control, positive control with 20 mg/kg body weight (BW) 5-fluorouracil, and three treatments with 25, 50, and 100 mg/kg BW FAs. The BW and tumor volume were recorded, and the COX-2, PGE2, and EP4 protein expression were measured and analyzed.Results: Using the predictive pkCSM algorithm, we found that FA did not cause developmental toxicity. Molecular simulations revealed that COX-2 and EP4 expression was inhibited by FA. An acute toxicity test conformed that the maximum tolerated FAs dose was >3.0 g/kg BW. The
引用
收藏
页数:15
相关论文
共 50 条
  • [31] LncRNA FTX activates FOXA2 expression to inhibit non-small-cell lung cancer proliferation and metastasis
    Jin, Shidai
    He, Jing
    Zhou, Yue
    Wu, Deqin
    Li, Jun
    Gao, Wen
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (08) : 4839 - 4849
  • [32] SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
    Mainardi, Sara
    Mulero-Sanchez, Antonio
    Prahallad, Anirudh
    Germano, Giovanni
    Bosma, Astrid
    Krimpenfort, Paul
    Lieftink, Cor
    Steinberg, Jeffrey D.
    de Wit, Niels
    Goncalves-Ribeiro, Samuel
    Nadal, Ernest
    Bardelli, Alberto
    Villanueva, Alberto
    Bernards, Rene
    NATURE MEDICINE, 2018, 24 (07) : 961 - +
  • [33] COX-2 overexpression and-8473 T/C polymorphism in 3' UTR in non-small cell lung cancer
    Bhat, Imtiyaz A.
    Rasool, Roohi
    Qasim, Iqbal
    Masoodi, Khalid Z.
    Paul, Shabeer A.
    Bhat, Bashir A.
    Ganaie, Farooq A.
    Aziz, Sheikh A.
    Shah, Zafar A.
    TUMOR BIOLOGY, 2014, 35 (11) : 11209 - 11218
  • [34] Downregulation of EIF4A2 in Non-Small-Cell Lung Cancer Associates with Poor Prognosis
    Xi Shaoyan
    Yong Juanjuan
    Tao Yalan
    He Ping
    Liang Jianzhong
    Wu Qinian
    CLINICAL LUNG CANCER, 2013, 14 (06) : 658 - 665
  • [35] Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis
    Xu, Yu-Qiong
    Long, Xiang
    Han, Ming
    Huang, Ming-Qiang
    Lu, Jia-Fa
    Sun, Xue-Dong
    Han, Wei
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (03) : 581 - 601
  • [36] Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression
    Li, Xiao-Lei
    Jia, Lan-Ling
    Shi, Mu-Mu
    Li, Xin
    Li, Zhong-Hua
    Li, Hui-Feng
    Wang, En-Hua
    Jia, Xin-Shan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [37] Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression
    Xiao-Lei Li
    Lan-Ling Jia
    Mu-Mu Shi
    Xin Li
    Zhong-Hua Li
    Hui-Feng Li
    En-Hua Wang
    Xin-Shan Jia
    Journal of Translational Medicine, 11
  • [38] Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis
    Zhan, Ping
    Qian, Qian
    Yu, Li-Ke
    JOURNAL OF THORACIC DISEASE, 2013, 5 (01) : 40 - 47
  • [39] COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKL signaling pathway-dependent manner
    Jiang, G-B
    Fang, H-Y
    Tao, D-Y
    Chen, X-P
    Cao, F-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (09) : 3838 - 3846
  • [40] Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE2
    Pun, Ivan Ho Yuen
    Chan, Dessy
    Chan, Sau Hing
    Chung, Po Yee
    Zhou, Yuan Yuan
    Law, Simon
    Lam, Alfred King Yin
    Chui, Chung Hin
    Chan, Albert Sun Chi
    Lam, Kim Hung
    Tang, Johnny Cheuk On
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 219 - 229